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Objectives. This study sought o determine the prognostic value 
of rest and exercise left ventricular ejection fraction in patients 
receiving thrombolytic therapy as part of the Thrombolysis in 
Myocardial Infarction (TIMI) trial. 
Background. In the prethrombolytic era, ejection fraction at 
rest as well as during exercise was an important prognostic index 
in patients recovering from acute myocardial infarction. The 
prognostic value of these measurements in the thrombolytic era is 
not clear. 
Methods. As part of the TIMI II protocol, we obtained radio- 
nuclide left ventricular ejection fraction at rest and during 
symptom-limited submaximal supine exercise. Measurements 
were related to 1-year all-cause as well as cardiac mortality. In 
addition, the relation between ejection fraction obtained at rest 
and 1-year cardiac mortality in this study was compared with the 
relation established previously in the prethrombolytic era by the 
Multicenter Postinfarction Research Group. 
Results. A distinct relation was noted between left ventricular 
ejection fraction at rest and all-cause mortality. The highest 
mortality rate (9.9%) was noted in patients with an ejection 
fraction <30%. Those not undergoing a study had a 1-year 
mortality rate of 6.2%. Peak exercise jection fraction provided 
prognostic information similar to that of rest ejection fraction. 
Likewise, change in ejection fraction from rest to exercise did not 
appreciably improve prognostic impact. 
Conclusions. Rest left ventricular ejection fraction is an impor- 
tant prognostic index in patients receiving thrombolytic therapy. 
Peak exercise jection fraction and the change in ejection fraction 
from rest to exercise do not provide appreciable prognostic data 
beyond those obtained at rest. Patients unable to exercise or those 
not having a rest study have a poor prognosis. When compared 
with the Multicenter Postinfarction Research Group data, there 
was strong evidence of a difference in survival in the two studies. 
At any level of ejection fraction, mortality was lower in TIMI II 
patients than in patients in the prethrombolytic era. 
(J Am Coll Cardiol 1995;26:73-9) 
In the prethrombolytic era, left vcntricular ejection fraction at 
rest and during peak exercise and the difference between peak 
exercise and rest ejection fraction were important prognostic 
indexes in both postinfarction patients and patients with stable 
coronary, disease (1-12). It has been suggested (13) that the 
effect of coronary reperfusion on survival and left ventricular 
function may not be related. That is, enhanccd survival after 
thrombolytic therapy may not be associated with concomitant 
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improvement in ventricular performance. It has also been 
suggested (14) that left ventricular ejection fraction should not 
be considered a surrogate nd point of trials of thrombolytic or 
adjunctive therapies, or both, for establishing myocardial 
reperfusion. Some questions about the utility of ejection 
fraction measurements concern the relation of global to re- 
gional function as well as the temporal sequence of improve- 
ment in function after reperfusion (14). 
In the Thrombolysis in Myocardial Infarction Phase II 
(TIMI II) clinical trial, patients presenting with ST segment 
elevation who were recruited within 4 h of the onset of chest 
pain were treated with intravenous recombinant tissue-type 
plasminogen activator (rt-PA) and were randomly assigned to 
either an invasive or conservative treatment strategy and 
treated with intravenous heparin and aspirin. At the time of 
hospital discharge, radionuelide ventriculography was per- 
formed at rest and during exercise. The purpose of the present 
report is to evaluate l-year survival on the basis of rest and 
exercise radionuclide left ventricular function assessed in this 
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large group of patients with acute myocardial infarction un- 
dergoing thrombolytic therapy. These prognostic data are 
compared with those obtained in the prethrombolytic era. 
Methods  
Study protocol. The details of the TIMI lI protocol have 
been described elsewhere (15). Briefly, eligibility criteria were 
age <76 years, chest discomfort characteristic of myocardial 
ischemia lasting ->30 min, ST segment elevation >0.1 mV in 
two contiguous electrocardiographic (ECG) leads, no contra- 
indication to thrombolytic therapy, feasibility of instituting 
such therapy within 4 h of onset of chest pain and patient 
consent. Patients received a 6-h infusion of rt-PA (alteplase 
[Activase] supplied by Genentech, Inc.) and were randomly 
assigned to either invasive or conservative strategies. 
Patients assigned to the invasive strategy were scheduled for 
coronary angiography and angioplasty, if feasible, 18 to 48 h 
after study entry. Coronary artery bypass urgery was recom- 
mended for invasive strategy in patients with coronary anatomy 
that was too complex or hazardous for angioplasty. Patients 
assigned to the conservative strategy underwent these proce- 
dures for spontaneous or provoked myocardial ischemia. Con- 
comitant therapy included intravenous infusion of hcparin and 
daily administration of aspirin tablets. Patients eligible for 
enrollment in a beta-adrenergic blocking agent herapy study 
(TIMI IIB) were also randomly assigned to receive either 
immediate intravenous or delayed oral administration f meto- 
prolol (16). 
Research nurse-coordinators from each participating clini- 
cal center were trained and certified in data collection, record- 
ing and data transfer to the coordinating center. For each 
patient, outcome was determined at the time of hospital 
discharge and 6 weeks, 6 months and 1 year after enrollment 
through clinic visits or telephone interview, or both. 
Rest-exercise quilibrium radionuclide ventriculography. 
Radionuclide-derived left ventricular ejection fraction was 
measured according to protocol in all patients. The protocol 
hospital discharge study was obtained an average of 9.3 days 
after study entry (range 2 to 38). Equilibrium radionuclide 
ventriculography was performed after modified in vivo red 
blood cell labeling according to standardized techniques 
(17,18). To ensure quality of data, before clinical participation 
in TIMI II began, each site was certified on the basis of 
provision of radionuclide studies of acceptable quality. 
Radionuclide ventriculography studies were initially ob- 
tained at rest, with the patient in the recumbent position. 
Thereafter, the patient was prepared for supine bicycle xer- 
cise. Repeat 2-min baseline measurements at rest were ac- 
quired with the patient's feet placed on the pedals of the 
bicycle ergometer. Radiolucent chest lead electrodes were 
used for ECG gating and monitoring during exercise. Exercise 
was begun at a work load of 200 kilopond-meters (kpm) and 
increased by 200 kpm after each 3-min stage. The exercise test 
at hospital discharge was limited to a maximal rate of 120 
beats/min, a maximal work load of 400 kpm or by development 
of angina or >2 mm ST segment depression, whichever came 
first. Ventricular function measurements were obtained uring 
the last 2 min of each 3-min stage of exercise. 
All data were acquired in ECG synchronized frame mode at 
16 frames/RR interval in a 64 x 64 matrix. The unsmoothed 
studies were stored on magnetic tape or floppy disks and were 
submitted to the radionuclide core laboratory for further 
analysis. In the core laboratory at Yale University, studies were 
transcribed to a central computer facility for temporal and 
spatial filtering and processing. Global left ventricular ejection 
fraction was determined from the image recorded in left 
anterior oblique view using previously standardized and vali- 
dated computer programs (17,18). The left ventricular volume 
curve corrected for background was filtered using four Fourier 
harmonics. Left ventricular ejection fraction was determined 
from the generated volume curve in the usual manner. In 
addition, regional function was assessed by measurement of 
regional ejection fraction from the same study. 
Statistical methods. Because survival through 1 year was 
comparable and global ejection fraction was similar for the two 
treatment strategies (invasive and conservative), data from 
both patient groups were combined in analyzing prognosis on 
the basis of radionuclide ventriculographic measures of left 
ventricular function. Survival was estimated using the product 
limit method (19), with p values taken from log-rank tests (20). 
For comparison with the published data of the Multicenter 
Postinfarction Research Group, TIMI II ejection fraction data 
were reclassified into four categories (>60%, 40% to 59%, 
20% to 39% and <20%) (1). For both studies, 99% confidence 
intervals for the proportion of patients who died in each 
category were calculated using standard methods (21). A 
logistic regression model, including ejection fraction category, 
research project (Multicenter Postinfarction Research Group 
[MPRG] or TIMI II) and an interaction term (ejection fraction 
by research project), was used to compare the mortality 
between the studies, taking into account differences in ejection 
fraction (22). 
To adjust for multiple comparisons, p values between 0.01 
and 0.001 for two-sided tests were specified as providing some 
evidence of differences, and p < 0.001 as providing strong 
evidence of differences. These analyses were performed using 
Statistical Analysis System (SAS) programs (23). The prognos- 
tic value of radionuclide ventriculographic variables and base- 
line characteristics were evaluated using Cox proportional 
hazards regression models (24) and Biomedical Data Package 
(BMDP) programs (25). Patient characteristics included in 
these models were gender, race, previous infarction, infarct 
location (anterior or nonanterior), history of angina, history of 
congestive heart failure, history of hypertension, history of 
diabetes, presence of painful ischemia (chest pain reported to 
the clinical center staff by the patient) at the time of initiation 
of thrombolytic therapy, age and time from onset of symptoms 
to treatment. Analyses were based on the final TIMI II data 
file. 
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Table 1. One-Year All-Cause Mortality Versus Rest Ejection 
Fraction at Hospital Discharge 
Rest EF at 
Hospital Discharge No. of No. (%) of 
(%) Pts Deaths 99% CI 
No study 630 39 (6.2) 4.2-9.2 
<30 162 16 (9.9) 5.3-18.0 
30-39 355 11 (3.1) 1.4-6.6 
40-49 604 13 (2.2) 1.1-4.4 
50-59 835 10 (1.2) 0.5-2.7 
->60 611 8 (1.3) 0.5-3.2 
Total 3,197 97 (3.0) 2.4-3.9 
CI = confidence interval; EF = ejection fraction; Pts = patients. 
Results 
Patient population. Of the total of 3,339 patients enrolled 
in TIMI II, 1,681 were randomly assigned to the invasive 
strategy, and 1,658 to the conservative strategy. The baseline 
clinical characteristics of patients in each strategy were com- 
parable (15). A total of 142 patients died before 14 days and 
did not have a radionuclide ventriculographic study. The 
remaining 3,197 patients form the prognostic study cohort. 
The vital status of all patients was known at 6 weeks from 
study entry. Follow-up at 1 year for mortality was complete for 
99.3% of patients. There were 97 deaths in the patient cohort; 
75 were attributed to cardiovascular causes. There were eight 
noncardiac deaths; of these six were related to malignancies. 
Thirteen deaths occurred from complications of therapy, in- 
cluding hemorrhagic stroke. Precise circumstances of one 
patient's death are not available to us. 
Availability of radionuclide ventriculographie data. In 772 
patients no or incomplete radionuclide ventriculographic data 
were available 14 days after study entry. In 187 of these 
patients the radionuclide ventriculogram was obtained after 14 
days. In 212 patients a radionuclide ventriculogram was ob- 
tained within 14 days, but ejection fraction could not be 
measured for technical reasons. In 74 patients, radionuclide 
ventriculography was not performed because of recent coro- 
nary bypass urgery. In 157 patients no radionuclide ventricu- 
lography was performed because of unstable cardiac status in 
51 or logistic considerations in 106, or both. The proportion of 
patients who did not survive 1 year in these groups ranged from 
2.7% to 12.1%. The radionuclide ventriculographic data were 
available for a total of 2,567 patients. 
Relation of mortality to rest left ventricular ejection frac- 
tion. The relation between all-cause mortality and rest hospi- 
tal discharge left ventricular ejection fraction is illustrated in 
Table 1 and Figure 1. The highest mortality rate (9.9%) was 
noted in patients with ejection fraction <30%. Ejection frac- 
tion >30% was associated with a relatively low 1-year mortali~ 
rate (range 1.2% to 3.1%). Of note, the 1-year mortality rate 
was 6.2% in those patients not undergoing study for any 
reason. 
Mortality varied, however, according to the reasons for 
missing radionuclide ventriculographic data. Those patients 
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Figure 1. Relation of rest ejection fraction to all-cause mortality in the 
TIMI II study. Note the hyperbolic shape of the curve and the 
mortality rate for patients who did not undergo radionuclide ventricu- 
lography within 14 days. 
having a study >14 days after study entry had a 2.7% mortality 
rate through 1 year from study entry. Those not undergoing 
radionuclide ventriculography because of a recent operation 
had an 8.1% mortality rate, and those not having a study for 
various cardiac and logistic reasons had a 12.1% mortality rate. 
Those with technically poor studies had a 4.2% mortality rate. 
Similar findings were noted for cardiovascular mortality and 
all-cause mortality. 
Kaplan-Meier analyses indicated a high early mortality in 
those patients who did not undergo radionuclide ventriculo- 
graphic study as well as in those with an ejection fraction 
<30% (Fig. 2). There was a relatively low mortality rate in 
patients with an ejection fraction >30%. There was little 
difference between those with an ejection fraction of 30% to 
49% and those with an ejection fraction ->50%. Most deaths 
occurred within the first 6 weeks of study entry. 
Relation of mortality to exercise ejection fraction. Peak 
exercise jection fraction was also evaluated as a prognostic 
index (Table 2). A total of 1,045 patients had no exercise study 
within 14 days. The mortality rate was high in this group 
(5.8%). For patients who did exercise, the peak exercise 
radionuclide ventriculogram provided prognostic information 
Figure 2. Kaplan-Meier analysis of mortality rate related to time from 
study entry, with patients categorized according to ejection fraction 
(EF). Mortality rate is highest in patients with ejection fraction <30%. 
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Table 2. One-Year All-Cause Mortality Versus Exercise Ejection 
Fraction at Hospital Discharge 
Exercise EF at No. of No. (%) of 
Discharge (%) Pts Deaths 99% C1 
No study 1,045 61 (5.8) 4.2-8.0 
<30 116 6(5.2) 1.8 14.1 
30-39 226 10 (4.4) 2.0-4.7 
40-49 418 8 (1.9) 0.8-4.7 
50-59 573 4 (0.7) 0.2-25 
>-60 819 8 (1.0) 0.4-2.4 
Total 3,197 97 (3.0) 2.4-3.9 
Abbreviations as in Table 1. 
similar to that provided by the rest ejection fraction (Fig. 3). 
Decrease in ejection fraction with exercise was associated with 
increased mortality (Fig. 4). 
Multivariate analysis. In the 2,567 patients with radionu- 
elide ventriculographic data at rest, ejection fraction was inversely 
associated with 1-year mortality: Lower ejection fraction was 
associated with increased mortality (Cox model coetticient -0.048 
per unit of ejection fraction, p < 0.0001). Inability to exercise was 
also associated with mortality (Cox model coefficient - 1.045, p < 
0.001). Peak exercise jection fraction and change in ejection 
fraction from rest to exercise did not appreciably improve the 
predictive accuracy. In those patients with both rest and exercise 
data (n -- 2,143, 1-year mortality rate 1.7%), rest ejection fraction 
remained the important predictor of mortality (Table 3). Of 
clinical variables, diabetes mellitus had the most important asso- 
ciation with mortality. 
Discussion 
Prognostic value of ejection fraction. The overall 1-year 
mortality in TIMI II is low. As reported previously, except for 
those patients with a previous myocardial infarction, no differ- 
ences in mortality exist between invasive and conservative 
strategy groups, either at hospital discharge or at 1 year 
follow-up (15,26). Our data demonstrate several relevant 
Figure 3. Relation of all-cause mortality to peak exercise jection 
fraction. Note again the hyperbolic shape of the survival curve and the 
impact of nonperformance of radionuclide v ntriculography on subse- 
quent mortality. 
10 
8 1 
>- 6 
_J 
IT  
O 
2 
Tota l  = 3197 
• <30% 
No study 
~'ithin 14 days 
40-49% % 
418 r N= 1045 I 116 i 226 I 573 I 819 
1 5 30  45  60  
PEAK EXERCISE  E JECT ION FRACTION (%)  
75  
10 
~6 
- -  NO study within 14 days (n=1045) 
.......... EF decrease 25 (n=235) 
- - - .  EF no change (n=1035) 
- - -  EF increase ->5 (n=882) 
S 
2 .............. ~~ ............ ~ ...................................................... r [  ...................... ; .............. 
0 6 10 14 18 22 26 30 34 38 42 46 50 54 
WEEKS FROM STUDY ENTRY 
Figure 4. Kaplan-Meier analysis of the relation between mortality rate 
and time from study entry on the basis of ejection fraction (EF) 
response to exercise. Note that the highest mortality occurs in those 
patients who did not undergo radionuclide v ntriculography or who 
demonstrated a significant decrease in ejection fraction, 
findings. 1) Rest left ventricular ejection fraction, first identi- 
fied as an important prognostic index before the advent of 
thrombolytic therapy, also retains its importance in patients 
who have received this treatment. 2) Peak exercise jection 
fraction and the change in ejection fraction from rest to 
exercise do not provide appreciable prognostic data beyond 
that obtained from the rest ejection fraction alone. 3) Al- 
though heterogeneous as a group, patients unable to exercise 
or who did not have a rest radionuclide v ntriculographic study 
have a poor prognosis. 4) At any level of ejection fraction, 
mortality was lower in the TIMI II cohort han that observed 
in patients in the prethrombolytic era (MPRG). Thus, ejection 
fraction in patients receiving thrombolytic therapy still appears 
to provide relevant prognostic information. However, a normal 
or modestly impaired ejection fraction is associated with an 
exceedingly ow mortality rate in this patient population. 
Ejection fraction is easily measured noninvasively by rou- 
tine radionuclide techniques, and high quality reproducible 
data can be obtained routinely without he technical difficulties 
and invasive nature of contrast angiography, including compli- 
cating ventricular ectopic beats. Furthermore, the geometry 
independence of count-based measurements adds to the reli- 
ability and reproducibility of radionuclide ventriculographic 
assessments, particularly in patients with myocardial infarction 
and distorted ventricular geometry. 
Relation of preserved ventricular function and survival. 
Although there is a demonstrable relation between the overall 
level of global eft ventricular function as measured by ejection 
fraction and mortality, there nevertheless exists discordance 
between preservation of ventricular function and survival in 
patients treated with thrombolytic therapy. That is, enhanced 
survival may occur despite impaired systolic function. A num- 
ber of explanations have been offered for this disparity, 
including the so-called time-to-treatment paradox (13,15). It 
can be argued that early administration f thrombolytic ther- 
apy may salvage patients with very poor ventricular function 
who would otherwise have died if they had not received 
thrombolysis or if they had been treated later in the course of 
their infarction. In analyses limited to surviving patients, the 
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Table 3. Relation of Mortality to Baseline Variables and Rest Ejection Fraction at Hospital Discharge 
and Change in Ejection Fraction (exercise minus baseline) for 2,143 Patients 
Variable Coefficient* p Value 
Rest EF at hospital discharge 
Change in EF (exercise baseline) 
Male (vs. female) 
White (vs. nonwhite) 
Prior MI (vs. no prior MI) 
Anterior MI (vs. nonanterior MI) 
History of angina (vs. no history of angina) 
History of CHF (vs. no history of CHF) 
History of hypertension (vs. no history of hypertension) 
History of diabetes (vs. no history of diabetes) 
Pain at time of treatment initiation (vs. no pain at time of 
treatment initiation) 
Age (10-yr increments) 
Time from onset of symptoms totreatment <-2 h (vs. >2 h) 
-0.036 0.01 
-0.040 0.11 
-0.433 0.23 
-0.567 0.19 
0.721 0.06 
-0.328 0.37 
0.706 0.10 
-0.458 0.66 
0.400 0.25 
0.930 0.01 
0.148 0.78 
0.493 0.02 
0.079 0.84 
*Positive coefficients are associated with increased mortality for the first named of dichotomous variables, negative 
coefficients with increased mortality for the alternate (in parentheses). The positive coefficient for age indicates increasing 
mortaliW with increasing t0-year age intervals. The negative coefficient for rest ejection fraction (EF) at hospital 
discharge indicates increasing mortality with decreasing ejection fraction. CHF = congestive heart failure; MI = 
myocardial infarction. 
greater number of salvaged patients with relatively poor ven- 
tricular function may mask the overall gain in ejection fraction 
seen in other patients with reperfused coronary arteries and 
lower mean values for the entire group. However, the prob- 
lems entailed in comparisons of survivors may not influence 
the prognostic value of the ejection fraction measurement 
itself. Others have argued (27) that ejection fraction may be of 
limited value because the compensatory noninfarct zone hy- 
perkinesia often seen after infarction may lead to an augmen- 
tation of global measures. 
Comparison of TIMI  II and MPRG data. To compare our 
data with those obtained in the prethrombolytic era, the TIMI II 
cardiovascular mortality-left ventricular ejection fraction curve 
was compared with data from MPRG collected from 1979 to 1981 
(1). There is strong evidence of a difference (p = 0.001) between 
the survival curves of the two studies (Fig. 5). There were also 
clinical differences between the two groups (Table 4). The MPRG 
Table 4. Patient Characteristics and Radionuclide 
Ventriculographic Prognosis 
TIMI lI MPRG* 
n = 2,567 n = 866 
Characteristic (%) (%) p Value 
Baseline 
Male 84 78 < 0.01 
Age ->60 yr 40 43 > 0.10 
Prior MI 13 24 < 0.001 
Anterior MI 51 36 < 0.001 
Rales ->1/3 lung fields 3 14 < 0.001 
Heart rate ->90 beats/min 19 23 < 0.01 
Hospital course: ischemia* 24 33 < 0.00 l 
*Recurrent painful ischemic events in Thrombolysis in Myocardial Infarction 
(TIMI) II; angina in the Multicenter Postinfarction Research Group (MPRG). 
MI = myocardial infarction. 
patients had a smaller proportion of men and a higher prevalence 
of previous infarction, rales, heart rate ->90 beats/min, ischemia 
during the hospital period and ejection fraction <40%. There was 
a higher prevalence of anterior infarction in the TIMI II cohort. 
TIMI II involved more than three times the number of 
patients in MPRG. Clinical differences between groups were 
noted (Table 4). Despite clinical differences, the objective 
variable of measured ejection fraction was used to characterize 
the patients in both MPRG and TIMI  II. The effect that the 
clinical differences would have on mortality is not likely to be 
as great as the impact of thrombolytic therapy and revascular- 
ization, where appropriate. However, there are limitations 
inherent in using historical control subjects. Many clinical and 
Figure 5. Comparison of cardiovascular mortality rate curves in 
relation to rest ejection fraction. Note the increased mortality in the 
Multicenter Postinfarction Research Group (MPRG) studies at the 
lower levels of ejection fraction. The data from the Thrombolysis in 
Myocardial Infarction Phase II trial (TIMI II) have been regrouped 
according to specifications outlined in the MPRG study (1). Vertical 
bars represent confidence intervals. 
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therapeutic factors have changed in the interim in addition to 
the utilization of thrombolytic therapy. 
These data also suggest hat in addition to preserving left 
ventricular myocardium, thrombolytic and associated therapies 
may enhance survival at any particular level of left ventricular 
function by other mechanisms. The explanation for this is not 
readily apparent. Selection of patients for thrombolytic ther- 
apy may be a factor in the low mortality observed. However, 
these observations may provide additional support for the 
"open artery hypothesis" (27-33). A number of relevant 
pathophysiologic phenomena may occur after prompt opening 
of the occluded artery that may improve survival but not 
necessarily global ventricular function. The open infarct- 
related artery, as may be anticipated after thrombolysis, may 
result in substantial lteration in early ventricular remodeling. 
Left ventricular infarct expansion may be limited. In addition, 
changes may occur through preservation ofan epicardial rim of 
myocardium as well as through maintenance of effective dia- 
stolic properties of the left ventricle resulting from an open 
coronary artery (34). Thrombolysis may also have specific 
electrophysiologic effects that may influence mortality through 
prevention of major arrhythmias (35-38). After thrombolysis, 
infarcted tissue may be more homogeneous and may thus have 
improved electrical stability on this basis, independent of left 
ventricular function. Finally, there may be independent, still 
poorly defined effects of thrombolytic therapy on infarcted 
myocardium that may involve factors such as blood viscosity, 
alteration of collagenases and other cytoprotective effects 
(39-41). Concomitant therapy and appropriate revasculariza- 
tion for ischemia (provided according to the TIMI II protocol) 
may also have influenced survival. 
Conclusions. This report emphasizes the continued prog- 
nostic value of rest left ventricular ejection fraction measure- 
ment before discharge in patients receiving thrombolytic ther- 
apy. Ejection fraction measurement should be considered 
along with other clinical variables previously defined in TIMI 
II (26,41-46). Despite relatively low mortality in the entire 
cohort, low ejection fraction measurements identify those 
patients with a poor prognosis. Because ejection fraction at 
rest <30% was associated with highest mortality, this finding 
might be considered a surrogate nd point in clinical trials of 
thrombolysis. Those in whom measurements could not be 
obtained, for a variety of reasons, also experienced a poor 
outcome. Exercise measurement does not add to this prognos- 
tic assessment. 
References 
1. The Multicenter Postinfarction Research Group. Risk stratification and 
survival after myocardial infarction. N Engl J Med 1983;309:331-6. 
2. Schelbert HR, Henning H, Ashburn WL, et al. Serial measurements of left 
ventricular ejection fraction by radionuclide angiography early and late after 
myocardial infarction. Am J Cardiol 1976;38:407-15. 
3. Schulze RA Jr, Strauss HW, Pitt B. Sudden death in the year following 
myocardial infarction: relation to ventricular premature contractions in the 
late hospital phase and left ventricular ejection fraction. Am J Med 
1977;62:192-9. 
4. Corbett JR, Dehmer GJ, Lewis SE, et al. The prognostic value of submaxi- 
mal exercise testing with radionuclide ventriculography before hospital 
discharge in patients with recent myocardial infarction. Circulation 1981;64: 
535-44. 
5. Nicod P, Corbett JR, Firth BG, et al. Prognostic value of resting and 
submaximal exercise radionuclide ventriculography after acute myocardial 
infarction in high-risk patients with single and multivessel disease. Am J 
Cardiol 1983;52:30-6. 
6. Wasserman AG, Katz RJ, Cleary P, et al. Noninvasive detection of multives- 
sel disease after myocardial infarction by exercise radionuclide ventriculog- 
raphy. Am J Cardiol 1982;50:1242-7. 
7. Morris KG, Palmeri ST, Califf RB, et al. Value of radionuclide angiography 
for predicting specific ardiac events after acute myocardial infarction. Am J 
Cardiol 1985;55:318-24. 
8. Hung J, Goris ML, Nash E, et al. Comparative value of maximal treadmill 
testing, exercise thallium myocardial perfusion scintigraphy and exercise 
radionuclide ventriculography for distinguishing high- and low-risk patients 
soon after acute myocardial infarction. Am J Cardiol 1984;53:1221-7. 
9. Borer JS, Miller D, Schreiber T, et al. Radionuclide cineangiography in 
acute myocardial infarction: role in prognostication. Semin Nucl Med 
1987;17:89-94. 
10. Jones RH. Use of radionuclide measurements of left ventricular function for 
prognosis in patients with coronary artery disease. Semin Nucl Med 1987; 
17:95-103. 
11. Lee KL, Pryor DB, Pieper KS, et al. Prognostic value of radionuclide 
angiography in medically treated patients with coronary artery disease. A 
comparison with clinical and catheterization variables. Circulation 1990;82: 
1705-17. 
12. Norris RM, Barnaby PF, Brandt PWT, et al. Prognosis after recovery from 
first acute myocardial infarction: determinants of reinfarction and sudden 
death. Am J Cardiol 1984;53:408-13. 
13. Van de Weft F. Discrepancies between the effects of coronary reperfusion 
on survival and left ventricular function. Lancet 1989;1:1367-8. 
14. Califf RM, Harrelson-Woodlief L, Topoi EJ. Left ventricular ejection 
fraction may not be useful as an end point of thrombolytic therapy 
comparative trials. Circulation 1990;82:1847-53. 
15. The TIMI Study Group. Comparison of invasive and conservative strategies 
after treatment with intravenous tissue plasminogen activator in acute 
myocardial infarction. Results of the Thrombolysis in Myocardial Infarction 
(TIMI) Phase II Trial. N Engl J Med 1989;320:618-27. 
16. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred 
beta-blockade following thrombolytic therapy in patients with acute myocar- 
dial infarction. Circulation 1991;83:422-37. 
17. Wackers FJT, Terrin ML, Kayden DS, et al. Quantitative radionuclide 
assessment of regional ventricular function after thrombolytic therapy for 
acute myocardial infarction: results of Phase I Thrombolysis in Myocardial 
Infarction (TIMI) Trial. J Am Coil Cardiol 1989;13:998-1005. 
18. Zaret BL, Wackers FJT, Terrin ML, et al. Assessment ofglobal and regional 
left ventricular performance at rest and during exercise after thrombolytic 
therapy for acute myocardial infarction: results of the Thrombolysis in 
Myocardial Infarction (TIMI) II study. Am J Cardiol 1992;69:1-9. 
19. Kaplan KL, Meier P. Nonparametric estimation from incomplete observa- 
tions. J Am Stat Assoc 1958;53:457-81. 
20. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New 
York: Wiley, 1980:122-7. 
21. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York: 
Wiley, 1981:29-30. 
22. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: Wiley, 
1989:106-18. 
23. SAS Institute, Inc. SAS Users Guide: Statistics. 5tb ed. Cary (NC): SAS 
Institute; 1985:401-32,529-57,795-800. 
24. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc B 
1972;34:187-220. 
25. Dixon WJ, editor. BMDP Statistical Software. Berkeley (CA): Univ of 
California Press, 1985:576-94. 
26. Williams DO, Braunwald E, Knatterud G, et al. One-year esults of the 
Thrumbolysis in Myocardial Infarction Investigation (TIMI) Phase II trial. 
Circulation 1992;85:533-42. 
27. Tiefenbrunn AJ, Sobel BE. Timing of coronary recanalization: paradigms, 
paradoxes, and pertinence. Circulation 1992;85:2311-5. 
28. Grines CL, Topoi EJ, Califf RM, et al. Predictors of enhanced regional wall 
JACC Vol. 26, No. 1 ZARET ET AL. 79 
July 1995:73-9 EJECTION FRACTION AND TIMI 1I SURVIVAL 
motion of the non-infarct zone after thrombolysis and angioplasty herapy of 
acute myocardial infarction. Circulation 1989;80:245-53. 
29. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of 
left ventricular dysfunction, and improved survival: should the paradigm be 
expanded? Circulation 1989;79:441-4. 
30. Kim CB, Braunwald E. Potential benefits of late reperfusion of infarcted 
myocardium. The open artery hypothesis. Circulation 1993;88:2426-36. 
31. Gersh BJ. Benefits of the open artery: beyond myocardial salvage. J Myocard 
Ischemia 1990;2:15-37. 
32. Cigarroa RG, Lange RA, Hillis LD. Prognosis after acute myocardial 
infarction in patients with and without residual anterograde coronary blood 
flow. Am J Cardiol 1989;64:155-60. 
33. Grines CL, DeMaria AN. Optimal utilization of thrombolytic therapy for 
acute myocardial infarction: concepts and controversies. J Am Coil Cardinl 
1990;16:223-31. 
34. Levy WC, Cerqueira MD, Litwin PE, Martin JS, Stratton JR, Weaver WD, 
and the MITI Investigators. A patent infarct related artery improves diastolic 
filling after thrombolytic therapy: Myocardial Infarction Triage and Inter- 
vention (MITI) trial [abstract]. Circulation 1992;86: Suppl 1:1-455. 
35. Vermeer F, Simoons ML, Lubsen J. Reduced frequency of ventricular 
fibrillation after early thrombolysis n myocardial infarction. Lancet 1986;1: 
1147-8. 
36. Sager P'[, Perlmutter RA, Rosenfeld LE, et al. Electrophysiologic effects of 
thrombolytic therapy in patients with a transmural anterior myocardial 
infarction complicated by left ventricular aneurysm formation. J Am Coil 
Cardiol 1988;12:19-24. 
37. Gang ES, Lew AS, Hong M, et al. Decreased incidence of ventricular late 
potentials after successful thrombolytic therapy for acute myocardial infarc- 
tion. N Engl J Med 1989;321:712-6. 
38. McClements B, Trouton TG, Mackenzie G. Which factors determine the 
development of late potentials after first myocardial infarction? A multifac- 
torial analysis. PACE Pacing Clin Electrophysiol 1991;14:1998-2003. 
39. Peuhkurinen KJ, Risteli L, Melkko JT, et al. Thrombolytic therapy with 
streptokinase timulates collagen breakdown. Circulation 1991;83:1969-75. 
40. Puckett SW, Digerness SB, Bowden HR, et at. Direct effects of streptokinase 
on the isolated rat myocardium. J Cardiovasc Pharmacol 1984;6:1120-3. 
41. Fung AYM, Rabkin SW. Beneficial effects of streptokinase on left ventric- 
ular function after myocardial reoxygenation and reperfusion following 
global ischemia in the isolated rabbit heart. J Cardiovasc Pharmacol 
1984;6:429-35. 
42. Mueller HS, Cohen LS, Braunwald E, et al. Predictors of early morbidity and 
mortality after thrombolytic therapy of acute myocardial infarction. Analyses 
of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) 
trial, Phase II. Circulation 1992;85:1254-64. 
43. Rogers W J, Bourge RC, Papapietro SE, et al. Variables predictive of good 
functional outcome following thrombolytic therapy in the Thrombolysis in 
Myocardial Infarction Phase II (TIMI II) pilot study. Am J Cardiol 
1989;63:503-12. 
44. Becket RC, Terrin M, Ross R, et at. Comparison of clinical outcomes for 
women and men after acute myocardial infarction. Ann Intern Med 1994; 
120:638. 
45. Terrin ML, Williams DO, Kleiman NS, et al. Two- and three-year results of 
the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. 
J Am Coil Cardiol 1993;22:1763-72. 
46. Ruocco NA, Bergelson BA, Jacobs AK, Frederick MM, Faxon DP, Ryan TJ. 
Invasive versus conservative strategy after thrombolytic therapy for acute 
myocardial infarction in patients with antecedent angina. J Am Coil Cardiol 
1992;20:1445-51. 
